Quick Facts

• Primary Therapeutic Use: Attention-Deficit/Hyperactivity Disorder (ADHD)
• Target Population: Children (six years and older), adolescents, and adults
• Therapeutic Action: Aims to improve attention span and reduce both impulsive behavior and excessive activity

---

Страттера, which contains the active substance atomoxetine, is a prescription medication utilized in a comprehensive treatment plan for Attention-Deficit/Hyperactivity Disorder (ADHD). The medicine is indicated for use in children who are at least six years old, as well as in adolescents and adults who have been diagnosed with ADHD.

Its therapeutic action is thought to be related to the selective inhibition of the presynaptic norepinephrine transporter in the brain. By affecting this neurotransmitter system, atomoxetine helps to manage the core symptoms of ADHD. The established benefits of treatment include an increase in the ability to pay attention and a decrease in impulsiveness and hyperactivity.

Clinical trials have demonstrated the efficacy of atomoxetine in controlling the symptoms of the disorder across the approved age groups. This medication is classified as a non-stimulant and is often used as an alternative or an addition to other treatments for ADHD.

The official regulatory profile for atomoxetine defines precise rules for patient eligibility.

Approved Age Groups and Contraindications

Classification	Eligible Population	Prohibited Population
Established Use	Children mathbf6 years and older, adolescents, and adults.	Children under 6 years and the geriatric population (use not established).
Non-Eligibility		Patients with narrow-angle glaucoma or pheochromocytoma (or history of).
Contraindication		Patients with known hypersensitivity to atomoxetine or product components.
MAOI Restriction		Use within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI) is strictly prohibited.

Cardiovascular Restrictions: The medicine is contraindicated in patients with severe cardiac or vascular disorders that would deteriorate with clinically important increases in heart rate or blood pressure, including known serious structural cardiac abnormalities [1.6, 1.10]. Individuals with pre-existing hypertension or tachycardia are specified for use with caution [2.5].

Organ and Metabolic Status: Patients with moderate or severe hepatic insufficiency (liver impairment) are eligible but require a mandated dose reduction [1.8]. Patients known to be CYP2D6 Poor Metabolizers also require a dose adjustment [1.5]. No dose adjustment is necessary for patients with renal impairment [1.7].

Pregnancy and Lactation: Use during pregnancy is not recommended unless the potential benefit justifies the potential risk to the fetus [1.7, 1.9]. For nursing mothers, a decision must be made to discontinue either breastfeeding or the drug due to a lack of data on excretion into human milk [1.1, 2.8].

Страттера Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Страттера (Atomoxetine) as described in authoritative government regulatory sources.

---

Formal Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors ( MAOIs) is strictly prohibited. A mandatory separation window of at least two weeks is required after discontinuing an MAOI before initiating Страттера, and vice versa.

---

Documented Pharmacokinetic and Pharmacodynamic Effects

Interacting Substance/Class	Interaction Type	Official Constraint/Note
Potent CYP2D6 Inhibitors	Pharmacokinetic (Metabolic)	Significantly increases Страттера systemic exposure ( AUC and C ss,max). Examples include Fluoxetine, Paroxetine, and Quinidine.
Beta2 Agonists (e.g., Albuterol)	Pharmacodynamic (Cardiovascular)	Caution is noted due to potential for potentiation of effects on heart rate and blood pressure.
Pressor Agents/Antihypertensives	Pharmacodynamic (Cardiovascular)	Caution is advised due to the risk of additive effects on heart rate and blood pressure.

---

Population and Administration Contexts

Food: The extent of Страттера absorption is minimally affected by food, allowing it to be taken with or without meals. Population Notes: CYP2D6 Poor Metabolizers and patients with moderate or severe hepatic impairment exhibit inherently higher atomoxetine systemic exposure compared to other groups.

Selective Norepinephrine Transporter Inhibition

The drug's core action is highly specific: it functions as a selective inhibitor of the presynaptic norepinephrine transporter (NET) protein. The NET is responsible for reabsorbing the neurotransmitter norepinephrine from the synaptic cleft back into the nerve terminal. Blocking the NET prevents this rapid reuptake, resulting in an increased extracellular concentration of norepinephrine in the synaptic cleft, which enhances its availability for binding to postsynaptic receptors.

---

Modulating Noradrenergic Pathways

By increasing the synaptic levels of norepinephrine, the drug modulates the signaling patterns across key noradrenergic pathways in the brain, particularly those projecting to the prefrontal cortex. This mechanism adjusts the dynamics of central signaling, altering the subsequent activity of noradrenergic receptors within these defined circuits.

---

Influence on Regulatory Feedback

This sustained mechanistic activity influences the regulatory feedback mechanisms within the targeted neural networks. The long-term adjustment of this system affects downstream receptor sensitivity, contributing to modified activity patterns across affected circuits.

Instruction Map: How to use Страттера — Administration Guidelines

Atomoxetine (Страттера) is for oral administration only and is typically used in the management of its primary approved indication across children (aged six and older), adolescents, and adults. The medicine is supplied as hard-shell capsules that must be swallowed whole and must not be opened, crushed, or chewed. Dosing may be taken with or without food.

---

Administration Scope

Category	Instruction Details
Route of administration	Oral administration only.
Timing in relation to meals (if applicable)	May be taken with or without food.
Age-group administration rules	Approved for use in patients aged six years and older. Dosing is weight-based for those le 70 kg.
Missed-dose rules	If a dose is missed, it should be taken as soon as possible, but the total prescribed dose must not be exceeded in any 24-hour period.

---

Labeled Dosing Regimens and Frequency

Administration follows a structured titration process that begins with a low starting dose, which is maintained for a minimum period (e.g., 3 to 7 days, depending on the region) before any increase is considered. This ensures the patient begins treatment within official guidelines.

• Adults (gt 70 kg): Initial daily dose is 40 mg. The target total daily dose is 80 mg, with a maximum recommended dose of 100 mg.
• Children/Adolescents (le 70 kg): Initial daily dose is approximately 0.5 mg/kg/day. The target maintenance dose is approximately 1.2 mg/kg/day.

Treatment is administered once daily (usually in the morning) or in two evenly divided daily doses (morning and late afternoon/early evening).

---

Special Procedural Conditions

Labeled instructions require explicit dose modification for specific populations to regulate systemic exposure: The initial and target daily doses must be reduced by 50% for patients with moderate hepatic impairment and by 75% for patients with severe hepatic impairment. Conversely, no dose adjustment is required for renal impairment.

Research Evidence / Overview of Studies for Страттера

Evidence for Core Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD)

The primary research foundation for atomoxetine consists of numerous short-term, randomized controlled trials (RCTs). In these foundational studies, the medicine was typically evaluated against an inactive substance (placebo). This research examined whether atomoxetine was associated with changes in the approved age groups, including children, adolescents, and adults who have been diagnosed with ADHD.

Studies were conducted to monitor whether atomoxetine was associated with changes in the intensity and variability of symptoms related to inattention, hyperactivity, and impulsivity. These outcomes were measured using standardized rating scales completed by investigators and observers, such as parents or teachers. Research highlights changes measured during the study period, helping to contextualize how symptoms evolved in the observed populations.

Research on Specific Symptom Scales and Functional Outcomes

Research explored the use of atomoxetine beyond just core symptom counts. Studies examined outcomes reflecting daily functioning or activity level, using patient-reported outcomes describing perceived discomfort and functional imbalance. Specialized trials monitored physiological strain or stress and captured phases of heightened symptom activity.

Long-Term Studies and Maintenance Data

Controlled evidence for atomoxetine has primarily focused on short-term (6 to 12 weeks) and intermediate-term (up to 6 months) intervals. Research highlights changes measured during these defined time periods. Beyond six months, controlled evidence is less extensive. Longer-term data, sometimes extending up to two years, was observed in open-label extension studies, which limits the certainty of the findings regarding sustained outcomes over multiple years.

Gaps and Areas of Uncertainty in the Research

While extensive short-term evidence exists, the long-term change patterns are not fully established, particularly concerning functional and quality-of-life outcomes maintained over several years. Data for certain groups remain insufficient, and research is still ongoing to fully understand all aspects of atomoxetine’s use. Certainty remains low regarding long-term outcomes in all approved age groups when compared to the short-term findings.

Common questions about Страттера (FAQ)

Q: Can I take Страттера for a headache?

Страттера is indicated for the temporary relief of pain associated with headaches, and this is a common reason for its use. The product label indicates a typical adult dose is 200mg, taken as needed. The product labeling lists mild stomach upset as a potential side effect. If side effects persist, it's important to consult a healthcare professional. Страттера is one of the options available for quick pain relief.

Q: Is Страттера safe to use every day?

The safety profile for long-term daily use should be discussed with a healthcare provider. While occasional use may be considered generally safe for many people, consistent daily use carries different considerations. It is important to consult a healthcare professional regarding daily or long-term use, as they can assess your specific health needs. Страттера is indicated for relieving pain when it occurs; preventative use is not a standard indication.

Q: What is the maximum dose of Страттера I can take?

The maximum recommended daily dose, according to the label, is typically 1200mg. It is important to follow the dosage instructions on the product label or those provided by a healthcare professional. If the maximum recommended dose does not provide adequate relief, this should be discussed with a healthcare professional. The product label advises seeking immediate medical attention if serious side effects occur.

How to Store and Dispose of Strattera (Atomoxetine)

Strattera capsules must be stored and handled in accordance with official regulatory requirements to maintain product stability and ensure safety.

---

Storage Requirements

Store Strattera at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medication should be kept in its original container and must remain tightly closed to protect it from excess heat and moisture. A mandatory requirement is to keep the capsules out of the sight and reach of children.

---

Disposal Instructions and Handling

If a capsule is accidentally broken, the loose powder should be washed away with water right away, taking care to avoid contact with eyes. Unused or expired medication must be disposed of according to local requirements, preferably through a drug take-back program. It is prohibited to dispose of the medicine by flushing it down the toilet or pouring it into a drain.